ArticleHaematologica2024

Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.

Leo I Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.